Pharmacy World & Science

, Volume 29, Issue 3, pp 221–227 | Cite as

Survey of pharmacists’ attitudes towards interchangeable use of dry powder inhalers

  • Angela E. Williams
  • Henry ChrystynEmail author
Original Paper



It is a common cost-containment practice in some countries to dispense a cheaper, generic version of a prescribed medication. This presents few problems for most medications. However, dry powder inhalers used in asthma and COPD vary markedly in design and method of operation, so generic substitution may not be acceptable to patients or healthcare professionals. Patients dispensed an unfamiliar device in which they have received no training, risk poor inhalation technique with the potential for inadequate dosing and loss of disease control.


To assess the views of pharmacists towards interchangeable use of dry powder inhalers.


Community pharmacists in Australia, Canada, France, Germany, and the UK.


Following exploration of the key issues with international opinion leaders in respiratory management, a structured web questionnaire was developed for use in computer assisted web interviews. Fieldwork was carried out in March and April 2005. Main outcome measure: Responses to the web questionnaire were analysed by percentage of respondents or by mean or median score, as appropriate to the question.


A total of 254 pharmacists were included in the study. Just 6% of pharmacists considered that dry powder inhalers are interchangeable, with a high level of concern shown about interchangeable use (median score of 6 on a scale of 1, not at all concerned, to 7, extremely concerned). Patient confusion was the main concern, expressed by 77% of respondents. Pharmacists also envisaged substitution having an adverse impact on pharmacy stock levels (72%), patient device handling (70%), pharmacist workload (63%), patient compliance (56%) and outcomes for the patient (51%), with pharmacists in Germany having a particularly negative view and those in France generally the most positive. Despite the generally negative view of pharmacists about interchangeable use of dry powder inhalers, overall only 22% would contact the prescribing physician often/very often for approval of the substitution.


The study showed that only a small minority of pharmacists believe that dry powder inhalers can be used interchangeably, with the majority concerned about generic substitution of these products. Pharmacists in Germany were particularly negative about the interchangeable use of dry powder inhalers.


Asthma Generic substitution Inhalation devices Pharmacists’ perceptions Web questionnaire 


  1. 1.
    Chrystyn H. Do patients show the same level of adherence with all dry powder inhalers? Int J Clin Pract 2005;59(Suppl 149):19–25CrossRefGoogle Scholar
  2. 2.
    Labris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. J Clin Pharmacol 2003;56:600–12CrossRefGoogle Scholar
  3. 3.
    Gustafsson P, Taylor A, Zanen P, Chrystyn H. Can patients use all dry powder inhalers equally well? Int J Clin Pract 2005;59(Suppl 149):13–8CrossRefGoogle Scholar
  4. 4.
    Buchanan A, Pinnock H, Barnes J et al. Generic prescribing of breath actuated and dry powder inhalers in the UK. Prim Care Respir J 2002;11:95Google Scholar
  5. 5.
    Bisgaard H. Future options for aerosol delivery to children. Allergy 1999;54:97–103PubMedGoogle Scholar
  6. 6.
    Taylor A, Gustafsson P. Do all dry powder inhalers show the same pharmaceutical performance?. Int J Clin Pract 2005;59(Suppl 149):7–12CrossRefGoogle Scholar
  7. 7.
    Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med 2001;14(S1):S19–S26PubMedCrossRefGoogle Scholar
  8. 8.
    Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 mcg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001;95:136–46PubMedCrossRefGoogle Scholar
  9. 9.
    BTS/SIGN (British Thoracic Society/Scottish Intercollegiate Guidelines Network). British guideline on the management of asthma. Thorax 2003;58(suppl 1):i1–i94 Google Scholar
  10. 10.
    GINA (Global Initiative for asthma). Pocket guide for asthma management and prevention.
  11. 11.
    Thomas M, Williams AE. Are outcomes the same with all dry powder inhalers? Int J Clin Pract 2005;59(Suppl 149):33–5CrossRefGoogle Scholar
  12. 12.
    Price D. Do healthcare professionals think that dry powder inhalers can be used interchangeably? Int J Clin Pract 2005;59(Suppl 149): 26–9CrossRefGoogle Scholar
  13. 13.
    Booker R. Do patients think that dry powder inhalers can be used interchangeably? Int J Clin Pract 2005;59(Suppl 149): 30–2CrossRefGoogle Scholar
  14. 14.
    Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636–42PubMedCrossRefGoogle Scholar
  15. 15.
    Hoskins G, McCowan C, Neville RG et al. Risk factors and costs associated with an asthma attack. Thorax 2000;55:19–24PubMedCrossRefGoogle Scholar
  16. 16.
    Adams WP, Puchikian G, Taylor AS, Patel RM, Burke GP, Williams RL. Regulatory aspects of modification to innovator bronchodilator metered dose inhalers and development of generic substitutes. J Aerosol Med 1994;7:119–34PubMedCrossRefGoogle Scholar
  17. 17.
    Price D, Summers M, Zanen P. Could interchangeable use of dry powder inhalers affect patients?. Int J Clin Pract 2005;59(Suppl 149):3–6CrossRefGoogle Scholar
  18. 18.
    Wood KM, Boath EH, Mucklow JC, Blenkinsopp A. Changing medication: general practitioner and patient perspectives. Int J Phar Pract 1997;5:176–84Google Scholar
  19. 19.
    Zermansky AG, Petty DR, Raynor DK, Lowe CJ, Freemantle N, Vail A. Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice: a randomized controlled trial. Health Technol Assess 2002;6:1–86PubMedGoogle Scholar
  20. 20.
    Vidgren M, Kärkkäinen A, Karjalainen P et al. Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm 1988;42:211–6CrossRefGoogle Scholar
  21. 21.
    Thorsson L, Edsbacker S. Less variability in lung deposition of budesonide via Turbuhaler than of fluticasone via Diskus/Accuhaler and pMDI in adults. Am J Respir Crit Care Med 2003;167(Suppl 7):A896Google Scholar
  22. 22.
    Kesten S, Zive K, Chapman KR. Pharmacist knowledge and ability to use inhaled medication delivery systems. Chest 1993;104:1737–42PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  1. 1.GlaxoSmithKlineGreenford, MiddlesexUK
  2. 2.School of PharmacyUniversity of Bradford BradfordUK

Personalised recommendations